Online inquiry

IVTScrip™ mRNA-Human ARHGAP25, (Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WK23190MR)

This product GTTS-WK23190MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the ARHGAP25 protein. This product can be used in Effector CD8+ memory T (Tem) cell-related researches.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Human
RefSeq NM_001007231.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification Chromatography
Target Gene
Gene ID 9938
UniProt ID P42331
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Human ARHGAP25, (Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WK23190MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WK19717MR IVTScrip™ mRNA-Human ANKRD31, (Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ANKRD31
GTTS-WK14932MR IVTScrip™ mRNA-Human ANKRD6, (Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ANKRD6
GTTS-WK24424MR IVTScrip™ mRNA-Human ARID3B, (Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA ARID3B
GTTS-WK26767MR IVTScrip™ mRNA-Human ARF5, (Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ARF5
GTTS-WK21803MR IVTScrip™ mRNA-Human ASCC2, (Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA ASCC2
GTTS-WK13897MR IVTScrip™ mRNA-Human AC133, (Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA AC133
GTTS-WK24165MR IVTScrip™ mRNA-Human ARPC1A, (Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ARPC1A
GTTS-WK24611MR IVTScrip™ mRNA-Human APLNR, (Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA APLNR
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW